Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • PMN310 | Amyloid-Beta
    • PMN267 | TDP-43
    • PMN442 | Alpha-Synuclein
    • Vaccines
    • Posters & Publications
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Dec 2, 2021

ProMIS Neurosciences Shareholders Approve Special Resolution

Nov 17, 2021

A Second Independent Proxy Advisor, ISS, Recommends ProMIS Neurosciences Shareholders Vote for the Share Consolidation

Nov 12, 2021

ProMIS Neurosciences Announces Third Quarter 2021 Results

Nov 2, 2021

Glass Lewis Recommends ProMIS Neurosciences Shareholders Vote for the Share Consolidation at the Upcoming Special Meeting

Oct 22, 2021

ProMIS Neurosciences Announces Update to Senior Management Team

Oct 22, 2021

ProMIS Neurosciences Appoints Accomplished Biotech Executive, Dr. Maggie Shafmaster, to its Board of Directors

Oct 21, 2021

ProMIS Neurosciences Files Special Meeting Proxy Material

Oct 7, 2021

ProMIS Neurosciences Announces Special Shareholder Meeting

Sep 15, 2021

ProMIS Neurosciences to Present at the Second Annual Undruggable Leaders Forum, September 15-16, 2021

Sep 13, 2021

ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 23rd Annual Investment Conference

  • arrow_back
  • 1…
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • …25
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2025 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy